Archive · 23 Jul 2025
Dr. Reddy's Q1 FY26 Profit Up Marginally, Revenue Climbs 11%
Dr. Reddy's, a medicine maker, made a little more money this past quarter.
They earned ₹1,409 crore, a small increase from last year.
While their overall sales went up because they sold more in other countries, they made less money in North America because of lower prices on a key medicine.
The company launched new products in the US and India, and they are working to improve their facilities based on inspections from the US government.
They have a lot of money saved up and may buy other companies.
Dr. Reddy's Q1 FY26 net profit increased marginally by 1% to ₹1,409 crore.
Revenue increased 11% to ₹8,545 crore, driven by growth in Europe and emerging markets.
Price erosion in North America, particularly for Lenalidomide, impacted profits.
The company launched five new products in the US and five new brands in the domestic market.
Dr. Reddy's received observations from USFDA at two facilities, which have been addressed.
- Who
- Dr. Reddy's Laboratories.
- What
- Dr. Reddy's Laboratories' Q1 FY26 financial results.
- When
- The first quarter ending June 30, 2025.
- Where
- Hyderabad, India, with operations in the US, Europe, India, and emerging markets.
- Why
- To report on the company's financial performance, highlighting revenue, profit, and market trends.
Company Performance
Market Dynamics
Impact of Price Erosion
Company Performance
Price erosion is a significant challenge.
Market Dynamics
Overall revenue growth indicates positive performance.
- Net Profit
- ₹1,409 crore (Q1 FY26)
- Revenue
- ₹8,545 crore (Q1 FY26)
- Revenue Growth
- 11%
- North America Revenue Decline
- 11%
- Europe Revenue Growth
- 140%
- Cash Surplus
- ₹2,922 crore